Filing Flows › Comparisons › ZBIO vs INBP
Zenas BioPharma vs Integrated Biopharma: ZBIO and INBP compared
Zenas BioPharma is the larger company: $10.0M of revenue in its latest quarter (Q3 2026) against $9.8M for Integrated Biopharma (Q4 FY26).
Where the money goes: ZBIO and INBP
Zenas BioPharma (ZBIO) · Q3 2026
Zenas BioPharma, Q3 2026: revenue $10.0M, net loss $109M, operating cash flow −$58.0M. The chart follows the revenue to costs, profit and cash.
Integrated Biopharma (INBP) · Q4 FY26
Integrated Biopharma, Q4 FY26: revenue $9.8M (-31% year over year), operating margin -8.9%, net loss $1.4M, operating cash flow −$1.2M. The chart follows the revenue to costs, profit and cash.
| Zenas BioPharma (ZBIO) | Integrated Biopharma (INBP) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q4 FY26 |
| Revenue | $10.0M | $9.8M |
| Revenue growth, Y/Y | — | -31% |
| Operating margin | n/m | -8.9% |
| Net earnings | −$109M | −$1.4M |
| Net margin | — | -13.9% |
| Operating cash flow | −$58.0M | −$1.2M |
Where the revenue comes from
Integrated Biopharma
- Contract Manufacturing: $9.5M (97%)
- Other Nutraceutical Business: $318K (3%)
Questions
Which is bigger, Zenas BioPharma or Integrated Biopharma?
Zenas BioPharma is the larger company: $10.0M of revenue in its latest quarter (Q3 2026) against $9.8M for Integrated Biopharma (Q4 FY26).
More: Zenas BioPharma earnings · how Zenas BioPharma makes money · Integrated Biopharma earnings · how Integrated Biopharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-K filed Sep 25, 2026). Fiscal quarters can end on different dates. Not investment advice.